Could Cardiovascular Systems, Inc. (CSII) Decline After Today’s Big Increase?

February 15, 2018 - By Richard Conner

Investors sentiment decreased to 0.79 in Q3 2017. Its down 0.18, from 0.97 in 2017Q2. It is negative, as 16 investors sold Cardiovascular Systems, Inc. shares while 50 reduced holdings. 10 funds opened positions while 42 raised stakes. 24.82 million shares or 3.05% more from 24.09 million shares in 2017Q2 were reported.
California Employees Retirement System holds 0% or 17,200 shares in its portfolio. Jacobs Levy Equity Management accumulated 143,320 shares. The Maryland-based Hussman Strategic Advsrs Inc has invested 1.36% in Cardiovascular Systems, Inc. (NASDAQ:CSII). The Illinois-based Balyasny Asset Mgmt Limited Liability has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Hanseatic Serv invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Connecticut-based Point72 Asset L P has invested 0.06% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Schwab Charles Investment Management invested in 201,819 shares. Legal & General Group Inc Public Ltd reported 0% stake. 22,323 are owned by Royal Bank Of Canada. Credit Suisse Ag reported 39,814 shares. 11,192 are held by Glenmede Trust Na. Jennison Ltd Liability owns 22,647 shares. Manufacturers Life Insurance Co The accumulated 0% or 24,755 shares. Commonwealth Equity has 12,688 shares for 0% of their portfolio. Secor Cap Advsr Ltd Partnership holds 98,742 shares.

The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) is a huge mover today! The stock increased 6.41% or $1.35 during the last trading session, reaching $22.4. About 821,461 shares traded or 190.98% up from the average. Cardiovascular Systems, Inc. (NASDAQ:CSII) has risen 113.78% since February 15, 2017 and is uptrending. It has outperformed by 97.08% the S&P500.
The move comes after 8 months positive chart setup for the $744.09M company. It was reported on Feb, 15 by We have $24.42 PT which if reached, will make NASDAQ:CSII worth $66.97M more.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Ratings Coverage

Among 9 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Cardiovascular Systems had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Monday, August 10. The firm earned “Hold” rating on Thursday, September 21 by Raymond James. As per Thursday, February 8, the company rating was maintained by Leerink Swann. On Friday, August 21 the stock rating was upgraded by Zacks to “Sell”. As per Thursday, October 8, the company rating was maintained by Dougherty & Company. The rating was downgraded by Leerink Swann on Thursday, October 8 to “Market Perform”. The stock has “Hold” rating by Needham on Friday, December 15. Bank of America upgraded the stock to “Neutral” rating in Thursday, August 4 report. Needham maintained Cardiovascular Systems, Inc. (NASDAQ:CSII) on Thursday, August 3 with “Buy” rating. On Thursday, October 8 the stock rating was downgraded by Bank of America to “Underperform”.

More important recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were published by: which released: “Cardiovascular Systems, Inc. Announces First Patients Treated from Radial …” on February 14, 2018, also published article titled: “Cardiovascular Systems, Inc. Appoints Jeff Points as Chief Financial Officer”, published: “Cardiovascular Systems Inc. appoints Rhonda Robb as chief operating officer” on January 24, 2018. More interesting news about Cardiovascular Systems, Inc. (NASDAQ:CSII) was released by: and their article: “Cardiovascular Systems Expands Product Portfolio to Further Support Peripheral …” with publication date: January 18, 2018.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $744.09 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.